<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03228030</url>
  </required_header>
  <id_info>
    <org_study_id>15-387</org_study_id>
    <nct_id>NCT03228030</nct_id>
  </id_info>
  <brief_title>Thiamine Supplementation in Heart Failure: a Pilot Randomized Controlled Crossover Trial</brief_title>
  <acronym>THIAMINE-HF</acronym>
  <official_title>Thiamine Supplementation in Heart Failure: a Pilot Randomized Controlled Crossover Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hamilton Health Sciences Corporation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>McMaster/St. Peter's Hospital Chair of Aging</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>McMaster University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Heart failure (HF) is a major cardiovascular disease with increasing prevalence. Thiamine&#xD;
      deficiency is common in HF patients. Previous small studies have shown that thiamine&#xD;
      supplementation can improve left ventricular systolic function in HF, but larger clinical&#xD;
      studies are lacking. Given the ease of supplementation and the potential benefits in HF, we&#xD;
      aim to conduct a pilot randomized controlled trial (RCT) using high dose thiamine&#xD;
      supplementation in HF patients. The main goal of this pilot study is to determine the&#xD;
      feasibility of recruitment for an RCT of thiamine supplementation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2, 2018</start_date>
  <completion_date type="Actual">April 30, 2021</completion_date>
  <primary_completion_date type="Actual">April 30, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recruitment</measure>
    <time_frame>11 months</time_frame>
    <description>Number of participants recruited during the study period. This is a feasibility outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Refusal rate</measure>
    <time_frame>11 months</time_frame>
    <description>Number of eligible individuals refusing to participate in the research study. This is a feasibility outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retention rate</measure>
    <time_frame>11 months</time_frame>
    <description>Number of participants completing the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance rate</measure>
    <time_frame>11 months</time_frame>
    <description>Proportion of participants with &gt;80% adherence to intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular ejection fraction (LVEF)</measure>
    <time_frame>3 months</time_frame>
    <description>Echocardiogram measurement of left ventricular ejection fraction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak global longitudinal strain (%)</measure>
    <time_frame>3 months</time_frame>
    <description>Speckle tracking echocardiogram measurement of heart contractility. This is a more sensitive measurement of heart function than LVEF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NT-proBNP</measure>
    <time_frame>3 months</time_frame>
    <description>Heart failure biomarker</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New York Heart Association (NYHA) class</measure>
    <time_frame>3 months</time_frame>
    <description>Heart function symptom grading</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>3 months</time_frame>
    <description>Kansas City Cardiomyopathy Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HF hospitalizations</measure>
    <time_frame>7.5 months</time_frame>
    <description>Number of hospital stays &gt;24h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HF emergency room visits</measure>
    <time_frame>7.5 months</time_frame>
    <description>Number of hospital visits &lt;24h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death due to cardiovascular causes</measure>
    <time_frame>7.5 months</time_frame>
    <description>As adjudicated by study committee</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Heart Failure</condition>
  <condition>Heart Failure With Reduced Ejection Fraction</condition>
  <condition>Thiamine Deficiency</condition>
  <condition>Congestive Heart Failure</condition>
  <arm_group>
    <arm_group_label>Thiamine mononitrate 500mg po daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 months on thiamine, followed by 6 week washout period, and then 3 months on placebo arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>3 months on placebo, followed by 6 week washout period, and then 3 months on thiamine</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Thiamine</intervention_name>
    <description>Capsules</description>
    <arm_group_label>Thiamine mononitrate 500mg po daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Identical capsules</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥60&#xD;
&#xD;
          -  NYHA class II-IV symptoms&#xD;
&#xD;
          -  Recent HF-related admission in past 12 months OR NT-proBNP &gt;600ng/L within 60 days of&#xD;
             screening&#xD;
&#xD;
          -  LVEF ≤45% on 2D/3D echocardiography or radionuclide angiography (RNA) in the past 12&#xD;
             months (on optimal therapy)&#xD;
&#xD;
          -  Medically optimized prior to enrolment with angiotensin converting enzyme inhibitor or&#xD;
             angiotensin receptor blocker (± neprilysin inhibitor), β-blocker, and/or aldosterone&#xD;
             antagonist at target or maximally tolerated doses.&#xD;
&#xD;
          -  Patients must be stable on medications without hospitalization in the past month.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Taking &gt;2.5mg/d of thiamine supplement. Allows standard multivitamin. B complex&#xD;
             vitamin not allowed due to high thiamine content.&#xD;
&#xD;
          -  Unable to swallow study medication. A placebo swallowing test will take place at&#xD;
             screening.&#xD;
&#xD;
          -  Clinical indication for thiamine supplementation including symptomatic thiamine&#xD;
             deficiency (Wernicke's encephalopathy, severe malnutrition, refeeding syndrome) and&#xD;
             heavy alcohol use, &gt;15 standard drinks per week in men and &gt;10 standard drinks per&#xD;
             week in women.&#xD;
&#xD;
          -  End-stage renal disease on dialysis&#xD;
&#xD;
          -  Severe mitral valve disease because this impacts the accuracy of speckle tracking&#xD;
             analysis on echocardiography.&#xD;
&#xD;
          -  Non-English speaking (unable to complete questionnaires).&#xD;
&#xD;
          -  Unable to provide written consent.&#xD;
&#xD;
          -  Cognitive impairment without a caregiver administering medications.&#xD;
&#xD;
          -  Expected survival &lt;1 year due to non-cardiac disease.&#xD;
&#xD;
          -  Expected heart transplantation in &lt;6 months (± left ventricular assistive device).&#xD;
&#xD;
          -  Allergies to the ingredients of the study medication or placebo&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric KC Wong, MD FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>McMaster University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>McMaster University</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 20, 2017</study_first_submitted>
  <study_first_submitted_qc>July 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2017</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>thiamine</keyword>
  <keyword>heart failure</keyword>
  <keyword>heart failure with reduced ejection fraction</keyword>
  <keyword>geriatric</keyword>
  <keyword>thiamin</keyword>
  <keyword>vitamin b1</keyword>
  <keyword>congestive heart failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Thiamine Deficiency</mesh_term>
    <mesh_term>Beriberi</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thiamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

